Rachel Vatnsdal
Stock Analyst at JP Morgan
(3.27)
# 940
Out of 5,182 analysts
68
Total ratings
53.19%
Success rate
14.55%
Average return
Main Sectors:
Stocks Rated by Rachel Vatnsdal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RVTY Revvity | Maintains: Neutral | $100 → $105 | $85.18 | +23.27% | 5 | Feb 3, 2026 | |
| ADPT Adaptive Biotechnologies | Maintains: Overweight | $17 → $20 | $14.04 | +42.45% | 6 | Nov 6, 2025 | |
| HSIC Henry Schein | Maintains: Overweight | $80 → $76 | $76.12 | -0.16% | 4 | Aug 7, 2025 | |
| AVTR Avantor | Maintains: Overweight | $17 → $14 | $7.86 | +78.12% | 1 | Aug 4, 2025 | |
| ILMN Illumina | Maintains: Neutral | $85 → $100 | $126.92 | -21.21% | 1 | Aug 1, 2025 | |
| CAI Caris Life Sciences | Initiates: Overweight | $31 | $18.44 | +68.11% | 1 | Jul 14, 2025 | |
| TXG 10x Genomics | Maintains: Neutral | $12 → $9 | $21.37 | -57.88% | 4 | May 9, 2025 | |
| TWST Twist Bioscience | Maintains: Underweight | $40 → $33 | $59.15 | -44.21% | 2 | May 6, 2025 | |
| RGEN Repligen | Maintains: Overweight | $200 → $190 | $117.43 | +61.80% | 6 | Apr 29, 2025 | |
| NVST Envista Holdings | Maintains: Neutral | $20 → $19 | $26.49 | -28.27% | 4 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $380 → $390 | $300.73 | +29.68% | 4 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $50 → $55 | $51.10 | +7.63% | 3 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $55 | $83.09 | -33.81% | 1 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $165 → $160 | $114.87 | +39.29% | 6 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $650 → $670 | $470.22 | +42.49% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $17 → $20 | $4.84 | +313.22% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,300 → $1,400 | $1,262.48 | +10.89% | 2 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.58 | - | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $60 → $90 | $36.26 | +148.21% | 2 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $250 → $270 | $178.98 | +50.85% | 4 | Dec 20, 2023 |
Revvity
Feb 3, 2026
Maintains: Neutral
Price Target: $100 → $105
Current: $85.18
Upside: +23.27%
Adaptive Biotechnologies
Nov 6, 2025
Maintains: Overweight
Price Target: $17 → $20
Current: $14.04
Upside: +42.45%
Henry Schein
Aug 7, 2025
Maintains: Overweight
Price Target: $80 → $76
Current: $76.12
Upside: -0.16%
Avantor
Aug 4, 2025
Maintains: Overweight
Price Target: $17 → $14
Current: $7.86
Upside: +78.12%
Illumina
Aug 1, 2025
Maintains: Neutral
Price Target: $85 → $100
Current: $126.92
Upside: -21.21%
Caris Life Sciences
Jul 14, 2025
Initiates: Overweight
Price Target: $31
Current: $18.44
Upside: +68.11%
10x Genomics
May 9, 2025
Maintains: Neutral
Price Target: $12 → $9
Current: $21.37
Upside: -57.88%
Twist Bioscience
May 6, 2025
Maintains: Underweight
Price Target: $40 → $33
Current: $59.15
Upside: -44.21%
Repligen
Apr 29, 2025
Maintains: Overweight
Price Target: $200 → $190
Current: $117.43
Upside: +61.80%
Envista Holdings
Mar 6, 2025
Maintains: Neutral
Price Target: $20 → $19
Current: $26.49
Upside: -28.27%
Mar 6, 2025
Maintains: Neutral
Price Target: $380 → $390
Current: $300.73
Upside: +29.68%
Feb 25, 2025
Downgrades: Neutral
Price Target: $50 → $55
Current: $51.10
Upside: +7.63%
Feb 21, 2025
Maintains: Overweight
Price Target: $50 → $55
Current: $83.09
Upside: -33.81%
Nov 26, 2024
Maintains: Overweight
Price Target: $165 → $160
Current: $114.87
Upside: +39.29%
Sep 20, 2024
Maintains: Overweight
Price Target: $650 → $670
Current: $470.22
Upside: +42.49%
Aug 7, 2024
Maintains: Underweight
Price Target: $17 → $20
Current: $4.84
Upside: +313.22%
Aug 5, 2024
Maintains: Neutral
Price Target: $1,300 → $1,400
Current: $1,262.48
Upside: +10.89%
Apr 22, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.58
Upside: -
Feb 14, 2024
Upgrades: Overweight
Price Target: $60 → $90
Current: $36.26
Upside: +148.21%
Dec 20, 2023
Maintains: Overweight
Price Target: $250 → $270
Current: $178.98
Upside: +50.85%